Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study

A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment with prasugrel (in combination with aspirin) was associated with a 26 percent relative risk reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke, compared to treatment with clopidogrel (8.3 percent vs. 11.0 percent, respectively, p<0.0001).(1) This corresponds to a 2.7 percent absolute risk reduction for patients treated with prasugrel. The results of this analysis, which also examined clinical outcomes in two other cohorts of patients who were treated for acute coronary syndromes and underwent angioplasty with stenting, will help inform appropriate physician prescribing of prasugrel. These data were recently published online in the American Journal of Cardiology. The TRITON-TIMI 38 trial was sponsored by Daiichi Sankyo Co., Ltd. and Eli Lilly LLY.